Chandra Bhagat PharmaBOM:542934 69 ROA % is 5.69% as of Mar. 2026, which is 399% above its 10-year median of 1.14. GuruFocus rates BOM:542934 with a GF Score™ of 69/100 and a GF Value™ of ₹70.21 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 118 Medical Distribution companies, Chandra Bhagat Pharma ranks better than 63.56% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Chandra Bhagat Pharma's annualizedNet Income for the quarter that ended in Mar. 2026 was ₹52 Mil.
Chandra Bhagat Pharma's average Total Assets over the quarter that ended in Mar. 2026 was ₹912 Mil. Therefore, Chandra Bhagat Pharma's annualized ROA % for the quarter that ended in Mar. 2026 was 5.69%.
The historical rank and industry rank for Chandra Bhagat Pharma's ROA % or its related term are showing as below:
BOM:542934'
s ROA % Range Over the Past 10 Years
Min: 0.26 Med: 1.14 Max: 3.22
Current: 3.22
During the past 10 years, Chandra Bhagat Pharma's highest ROA % was 3.22%. The lowest was 0.26%. And the median was 1.14%.
BOM:542934's ROA % is ranked better than 63.56% of 118
companies
in the Medical Distribution industry
Industry Median: 2.215
vs BOM:542934: 3.22
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Mar. 2026) net income data. The Revenue data used here is two times the semi-annual (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Chandra Bhagat Pharma's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chandra Bhagat Pharma ROA % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Chandra Bhagat Pharma's ROA % distribution charts can be found below:
* The bar in red indicates where Chandra Bhagat Pharma's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Chandra Bhagat Pharma (BOM:542934) has a ROA % of 5.69% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Chandra Bhagat Pharma and its competitors. This is 399% above median its historical median of 1.14. Over the past decade, Chandra Bhagat Pharma's ROA % has ranged from 0.26 to 3.22. According to the industry distribution chart, Chandra Bhagat Pharma ranks #43 out of 118 companies in the Medical Distribution industry, placing it in the top 36.4%.
Is Chandra Bhagat Pharma's ROA % too high?
Chandra Bhagat Pharma's current ROA % of 5.69% is 399% above median its 10-year median of 1.14. Over the past 10 years, this metric has ranged from a low of 0.26 to a high of 3.22. The Medical Distribution industry median ROA % is 2.22. Chandra Bhagat Pharma's value of 5.69% is 156.9% above this industry median. Based on the distribution chart, Chandra Bhagat Pharma ranks #43 out of 118 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Chandra Bhagat Pharma has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Chandra Bhagat Pharma's ROA % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Chandra Bhagat Pharma ranks #43 out of 118 companies for ROA %. This puts Chandra Bhagat Pharma in the upper half of its industry. The industry median ROA % is 2.22. Chandra Bhagat Pharma's value of 5.69% is 156.9% above this benchmark. Historically, Chandra Bhagat Pharma's own ROA % has ranged from 0.26 to 3.22 over the past decade. While the company's 10-year median is 1.14 vs. the industry median of 2.22, Chandra Bhagat Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Distribution company?
The median ROA % among Medical Distribution companies is 2.22, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chandra Bhagat Pharma's current ROA % of 5.69% is 156.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Chandra Bhagat Pharma and its competitors. For the Medical Distribution industry, the median ROA % is 2.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chandra Bhagat Pharma's current ROA % is 5.69%, which is 399% above median its own 10-year median of 1.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chandra Bhagat Pharma stock overvalued right now?
Based on GuruFocus' analysis, Chandra Bhagat Pharma (BOM:542934) is currently considered Possible Value Trap. The stock's GF Value™ is ₹70.21, compared to a current price of ₹42.70 — trading 39.2% below its estimated fair value. The current ROA % is 5.69%, which is 399% above median its 10-year median of 1.14 and 156.9% above the Medical Distribution industry median of 2.22. Chandra Bhagat Pharma's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Chandra Bhagat Pharma (BOM:542934), the current ROA % is 5.69% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chandra Bhagat Pharma (BOM:542934) Overvalued in 2026?
Based on GuruFocus' analysis, Chandra Bhagat Pharma stock appears to be undervalued.
The current stock price of ₹42.70 is trading 39.2% below its estimated GF Value™ of ₹70.21.
GuruFocus considers Chandra Bhagat Pharma to be Possible Value Trap.
Key valuation signals for BOM:542934:
ROA %: 5.69% (399% above median its 10-year median of 1.14)
GF Value™: ₹70.21 vs. price of ₹42.70 (39.2% below fair value)
Industry Position: 156.9% above the Medical Distribution median (#43 of 118)
No single metric tells the full story. See the BOM:542934 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chandra Bhagat Pharma Ltd is a pharmaceutical company marketing pharmaceutical, critical care, and health care products across the globe. The company deals in many categories of pharmaceutical products like anticancer, cardiovascular, anti-infective, etc. It offers various forms of pharmaceutical products, like oral solids. tablets, capsules, liquid orals, syrup suspension, injections, liquid, powder, etc. Additionally, the company is also engaged in promoting and marketing of Active Pharmaceutical Ingredients (API's) in India.
69GF Score
Get the complete analysis for BOM:542934
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:542934 has been successfully added to your 
